Don't Let the HCT-CI Fool You: Similar Outcomes with Myeloablative CD34+Selected Allo-HCT Compared to Unmodified RIC Allo-HCT in Patients with AML or MDS and High Comorbidity Scores.

Pennisi, M; Cho, C; Devlin, SM; Ruiz, JD; Maloy, MA; Tomas, AA; Castillo, N; Lin, RJ; Politikos, L; Sanchez-Escamilla, M; Scordo, M; Shah, GL; Barker, JN; Castro-Malaspina, H; Gyurkocza, B; Dahi, PB; Jakubowski, AA; Papadopoulos, EB; Ponce, DM; Sauter, CS; Shaffer, BC; Shouval, R; Tamari, R; van den Brink, MRM; Young, JW; Giralt, SA; Perales, M

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020; 26 (3): S152

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索